Small molecule · Antagonist of substance P/neurokinin 1 (NK1) receptor (TACR1) · developed by Msd
ApprovedFDA, Mar 2003
3Registered trials
What is Aprepitant?
Aprepitant is a selective, high-affinity antagonist of the substance P/neurokinin 1 (NK1) receptor that crosses the blood-brain barrier and acts centrally. It is studied for and used in the prevention of nausea and vomiting, including chemotherapy-induced and postoperative nausea and vomiting.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Aponvie, Cinvanti, Emend, MK-0869, MK-869
Drug type
Small molecule
Targets
substance P/neurokinin 1 (NK1) receptor (TACR1)
Mechanism
Antagonist of substance P/neurokinin 1 (NK1) receptor (TACR1)
Pathways
substance P signaling, emesis (central nervous system)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.